Symrise AG (OTCMKTS:SYIEY – Get Rating) – Investment analysts at Jefferies Financial Group reduced their FY2024 earnings estimates for Symrise in a research report issued to clients and investors on Monday, January 9th. Jefferies Financial Group analyst C. Counihan now expects that the company will earn $1.17 per share for the year, down from their prior estimate of $1.18. The consensus estimate for Symrise's current full-year earnings is $0.88 per share. Jefferies Financial Group also issued estimates for Symrise's FY2025 earnings at $1.23 EPS.
Get Symrise alerts:Several other equities analysts have also commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Symrise from €107.00 ($115.05) to €110.00 ($118.28) in a research report on Monday, December 5th. The Goldman Sachs Group lowered shares of Symrise from a "buy" rating to a "neutral" rating in a research report on Sunday, November 27th. Finally, Morgan Stanley lowered shares of Symrise from an "equal weight" rating to an "underweight" rating in a research report on Monday, September 26th.
Symrise Price Performance
Shares of OTCMKTS:SYIEY opened at $27.95 on Thursday. The company's fifty day moving average is $27.70 and its two-hundred day moving average is $26.79. Symrise has a 1-year low of $22.20 and a 1-year high of $34.67.About Symrise
(Get Rating)
Symrise AG supplies fragrances, flavorings, cosmetic active ingredients and raw materials, and functional ingredients. It operates through two segments, Taste, Nutrition & Health, and Scent & Care. The Taste, Nutrition & Health segment provides functional ingredients and flavor solutions used in the production of food and beverages; savory flavors; natural and sustainable ingredients for food and beverage manufacturers, baby food, and dietary supplements; product solutions and services for pet food manufacturers; sustainable ingredients and services for aqua feed manufacturers to develop solutions for fish and shrimp farms; and probiotics for food supplements and functional foods.
Featured Articles
- Get a free copy of the StockNews.com research report on Symrise (SYIEY)
- Optimism About Global Demand For Metals Boosts BHP, Other Miners
- Exxon Mobil Expects Earnings and Cash Flow to Grow
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
Receive News & Ratings for Symrise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Symrise and related companies with MarketBeat.com's FREE daily email newsletter.